62.60% to Target, Chardan Capital Maintains Buy Rating for Vuzix (VUZI) Stock; Amedisys (AMED)’s Sentiment Is 1.71

Among 4 analysts covering Vuzix (NASDAQ:VUZI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vuzix has $11 highest and $7.0 lowest target. $10.25’s average target is 66.67% above currents $6.15 stock price. Vuzix had 12 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Thursday, December 10 with “Buy”. The company was reinitiated on Monday, September 28 by Chardan Capital Markets. As per Monday, June 26, the company rating was maintained by Maxim Group. Maxim Group initiated it with “Buy” rating and $11 target in Friday, October 28 report. The firm earned “Hold” rating on Friday, August 21 by Zacks. The firm has “Buy” rating by Chardan Capital Markets given on Monday, December 14. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 2 report. As per Thursday, December 10, the company rating was initiated by Rodman & Renshaw. Maxim Group maintained Vuzix Corporation (NASDAQ:VUZI) rating on Friday, November 10. Maxim Group has “Buy” rating and $11.0 target. On Wednesday, July 19 the stock rating was maintained by Maxim Group with “Buy”.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $1.83 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 42.78 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

The stock increased 4.24% or $0.25 during the last trading session, reaching $6.15. About 821,593 shares traded or 184.67% up from the average. Vuzix Corporation (NASDAQ:VUZI) has risen 11.43% since December 26, 2016 and is uptrending. It has underperformed by 5.27% the S&P500.

Vuzix Corporation designs, manufactures, markets, and sells wearable display devices in the United States and internationally. The company has market cap of $136.55 million. The companyÂ’s products are worn like eyeglasses that enable the user to view video and digital content, such as movies, computer data, the Internet, or video games. It currently has negative earnings. The Company’s products include binocular wearable displays that contain two micro displays mounted in a frame attached to eyeglass-style temples or stereo headphones; monocular smart glasses products for the enterprise, industrial, and commercial markets, as well as video headphones; augmented reality products, which provide the user a live, direct or indirect, view of a physical, and real-world environment; and video viewing glasses as mobile displays for entertainment and gaming for on-the-go users, as well as support for stepping into virtual worlds, simulations, and virtual reality gaming.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.42, from 0.67 in 2017Q2. It is positive, as 6 investors sold Vuzix Corporation shares while 5 reduced holdings. 5 funds opened positions while 7 raised stakes. 1.83 million shares or 6.52% more from 1.71 million shares in 2017Q2 were reported. 17,541 were accumulated by Virtu Fin Ltd Liability Co. 102,203 are held by Geode Limited Liability Company. New York-based Blackrock has invested 0% in Vuzix Corporation (NASDAQ:VUZI). Barclays Public Ltd Com stated it has 0% of its portfolio in Vuzix Corporation (NASDAQ:VUZI). Natl Bank Of Montreal Can holds 0% of its portfolio in Vuzix Corporation (NASDAQ:VUZI) for 207,500 shares. Ogorek Anthony Joseph New York Adv stated it has 0% in Vuzix Corporation (NASDAQ:VUZI). Lpl Financial Lc reported 15,100 shares. Bank Of New York Mellon has 0% invested in Vuzix Corporation (NASDAQ:VUZI) for 20,015 shares. Morgan Stanley reported 94,381 shares or 0% of all its holdings. Royal Fincl Bank Of Canada has 0% invested in Vuzix Corporation (NASDAQ:VUZI) for 676 shares. Northern Trust accumulated 0% or 38,083 shares. Oz Mngmt Limited Partnership, a New York-based fund reported 57,500 shares. Balyasny Asset Lc stated it has 100,000 shares or 0% of all its holdings. Carl Domino holds 0.22% or 33,000 shares. Deutsche National Bank Ag holds 0% of its portfolio in Vuzix Corporation (NASDAQ:VUZI) for 1,415 shares.

Since December 14, 2017, it had 2 insider purchases, and 0 sales for $43,740 activity. $28,720 worth of Vuzix Corporation (NASDAQ:VUZI) was bought by Boris Paul A. $15,020 worth of Vuzix Corporation (NASDAQ:VUZI) was bought by Harned Timothy Heydenreich.

Analysts await Amedisys, Inc. (NASDAQ:AMED) to report earnings on February, 27. They expect $0.59 EPS, up 34.09% or $0.15 from last year’s $0.44 per share. AMED’s profit will be $20.03M for 22.86 P/E if the $0.59 EPS becomes a reality. After $0.56 actual EPS reported by Amedisys, Inc. for the previous quarter, Wall Street now forecasts 5.36% EPS growth.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $50,000 activity.

Ratings analysis reveals 50% of Amedisys’s analysts are positive. Out of 2 Wall Street analysts rating Amedisys, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $47.0 while the high is $50.0. The stock’s average target of $48.50 is -10.09% below today’s ($53.94) share price. AMED was included in 2 notes of analysts from November 7, 2016. Benchmark initiated it with “Hold” rating and $50.0 target in Friday, January 27 report. Mizuho upgraded the stock to “Buy” rating in Monday, November 7 report.

Kohlberg Kravis Roberts & Co. L.P. holds 3.15% of its portfolio in Amedisys, Inc. for 4.84 million shares. Copper Rock Capital Partners Llc owns 575,315 shares or 2.14% of their US portfolio. Moreover, Fny Managed Accounts Llc has 1.18% invested in the company for 16,092 shares. The Connecticut-based Sivik Global Healthcare Llc has invested 1.05% in the stock. Redmile Group Llc, a California-based fund reported 283,648 shares.